Form 4: Acrivon Legal Chief Granted 129,760 Stock Options

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, received a grant of 129,760 stock options with a $1.51 exercise price, vesting over four years.

Summary

• Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), was granted 129,760 stock options.
• The stock options have an exercise price of $1.51 per share.
• The grant date for these options was March 1, 2026.
• The options are scheduled to expire on February 29, 2036.
• The vesting schedule dictates that 25% of the shares subject to the option will vest on March 1, 2027.
• The remaining shares will vest in 36 substantially equal monthly installments thereafter, contingent on continuous service by the reporting person.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive event, as it represents a routine compensation action that aligns management's interests with shareholders and aids in executive retention.

Positives

• The grant of stock options aligns the Chief Legal Officer's financial interests with those of shareholders, incentivizing long-term performance.
• This compensation structure serves as a retention tool, encouraging the Chief Legal Officer to remain with the company through the vesting period.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution for existing shareholders.

Risks

• This Form 4 filing primarily reports an insider transaction and does not detail company-specific operational or financial risks.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook, focusing solely on an insider's derivative securities transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into how officers and directors acquire or dispose of company securities. The grant of stock options is a common form of executive compensation in the biotechnology and pharmaceutical industries, aiming to align management incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as a component of executive compensation is a widely adopted practice across various industries, including biotechnology, aligning with typical compensation structures seen in companies like Moderna (MRNA) or BioNTech (BNTX) for their executives.
• The vesting schedule, with an initial cliff and subsequent monthly installments over several years, is a common mechanism designed to promote long-term retention and performance, comparable to equity incentive plans at peer companies.

Related Party Transactions

• The grant of stock options to Mary Miller, the Chief Legal Officer, constitutes a related party transaction as it involves compensation to an executive officer.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased alignment of executive incentives with company performance.
• Employees: The Chief Legal Officer benefits directly from the equity grant, enhancing personal wealth potential and long-term commitment to the company.

Next Steps

• The stock options will begin vesting on March 1, 2027, with subsequent monthly vesting installments over the following three years, subject to Mary Miller's continuous service.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Stock Option, Insider Transaction, Form 4, Executive Compensation, Mary Miller, Chief Legal Officer